DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Modality
Small molecule
Phase
Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: